

## Important Notes 重要提示

- 1 Manulife Global Fund – Dragon Growth Fund (the “Fund”) invests in a diversified portfolio of public companies listed in Hong Kong and/or having substantial business interest in Hong Kong and/or China, which may involve equity market, Mainland China investment, Stock Connect, geographical concentration, liquidity, volatility and taxation risks.
  - 2 The Fund does not guarantee distribution of dividends, the frequency of distribution, and the amount/rate of dividends. Dividends may be paid out of realized capital gains, capital and/or gross income while charging all or part of their fees and expenses to capital (i.e. payment of fees and expenses out of capital) in respect of MDIST (G) share class(es). Dividends paid or effectively paid out of capital amount to a return or withdrawal of part of the amount of an investor's original investment or from any capital gains attributable to that original investment, and may result in an immediate decrease in the Net Asset Value per Share in respect of the relevant class(es).
  - 3 The Fund intends to use financial derivative instruments (“FDIs”) for investment, efficient portfolio management and/or hedging purposes. The use of FDIs exposes the Fund to additional risks, including volatility risk, management risk, market risk, credit risk and liquidity risk.
  - 4 Investment involves risk. The Fund may expose its investors to capital loss. Investors should not base on this material alone to make investment decisions and should read the offering document for details, including the risk factors, charges and features of the Fund and its share classes.
- 1 宏利環球基金 – 巨龍增長基金（「本基金」）投資於香港上市及/或在香港及/或中國擁有重大業務權益的公開招股公司之多元化投資組合，可能涉及股票市場、中國內地投資、互聯互通、地域集中、流動性、波動性及稅務風險。
  - 2 本基金並不保證會作出股息分派、分派的頻次及股息款額或派息率。股息可從每月派息(G)類別股份的已變現資本收益、資本及/或總收益撥付股息，並從資本扣除全部或部分費用及開支(即從資本撥付費用及開支)。從資本中撥付或實際上從資本中撥付股息等於退回或提取投資者原本投資額的一部分或該原本投資額所產生的任何資本增值及可能導致相關類別的每股資產淨值即時減少。
  - 3 本基金擬使用金融衍生工具作投資、有效管理投資組合及/或對沖目的。金融衍生工具的使用導致本基金承受額外風險，包括波動風險、管理風險、市場風險、信用風險及變現風險。
  - 4 投資涉及風險。本基金的投資者或須承受資本虧損。投資者不應只單靠本資料而作出投資決定，而應仔細閱讀銷售文件，以獲取詳細資料，包括本基金及其股份類別之風險因素、收費及產品特點。

Fund prices may go down as well as up. Past performance information presented are not indicative of future performance. Investor has his/her own personal investment objectives, investment products may not be suitable for everyone.

基金價格可跌亦可升，過往業績數據並非未來業績的指標。投資者的目標各有不同，投資產品未必適合所有投資者。

This material has not been reviewed by the Securities and Futures Commission.

證券及期貨事務監察委員會並未審閱此文件。

Issued by Manulife Investment Management (Hong Kong) Limited.

由宏利投資管理(香港)有限公司刊發。

Information as of 資料截至 2021/06/30

## Investment Objective 投資目標

This Fund aims to achieve capital growth by investing at least 70% of its net assets in a diversified portfolio of equity and equity related securities of public companies which are listed in Hong Kong and/or, although not listed in Hong Kong, are listed on a stock exchange in any other jurisdiction and have substantial business interests in Hong Kong and/or China. Such equity and equity related securities include common stocks, preferred stocks and depositary receipts. While this Fund will invest in accordance with its investment objective and strategy, subject to applicable laws and regulations, this Fund is not otherwise subject to any limitation on the portion of its net assets that may be invested in any one country or sector and in issuers of any market capitalisation. Hence, this Fund may invest more than 30% of its net assets in issuers located in any of the People's Republic of China (the "PRC") and Hong Kong. This Fund's investments may be denominated in any currency.

本基金旨在透過將其最少70%的淨資產投資於多元化的公眾公司股票及股票相關證券組合，以達致資本增長。該等公司須在香港上市及/或儘管不在香港上市，亦須於任何其他司法管轄區的證券交易所上市，並在香港及/或中國有實質業務權益。該等股票及股票相關證券包括普通股、優先股及預託證券。投資策略儘管本基金會適用法規規限下遵照其投資目標及策略進行投資，惟子基金對於其淨資產投資於任何一個國家或行業及任何市值的發行機構的比例卻並無任何限制。因此，本基金會將其超過30%的淨資產投資於設於中國和香港任何一地的發行機構。本基金的投資可以任何貨幣計價。

## Fund Information 基金資料

Investment Manager 投資管理人	Manulife Investment Management (Hong Kong) Limited 宏利投資管理(香港)有限公司		
Launch Date (YYYY/MM/DD) 發行日期	1996/12/20		
Launch Price (per share) 發行價格(每股)	USD 1.00		
Base Currency 基礎貨幣	USD 美元		
Available Class(es) and their Bloomberg/ISIN Code 可選擇之類別及其彭博/ISIN編號	Bloomberg Ticker 彭博編號	ISIN Code ISIN編號	
Class A (USD) A(美元)類別	MNRIHKI	LU0085394210	
Fund Size 基金規模	USD 609.74 million 百萬		
Initial Charge 初次收費	Nil 不適用		
Redemption Charge 贖回費	1.00% within 2 years, no charge after 2 years 兩年內贖回收取1.00% · 兩年以上費用全免		
Switching Charge 轉換費	Up to 1.00% 最多達1.00%		
Management Fee <sup>*</sup> 管理費 <sup>*</sup>	1.50% per annum of the NAV of this fund 每年本基金資產淨值的 1.50%		
Minimum Initial Investment 最低初次投資額	HKD 1,560,000		
Minimum Subsequent Investment 最低其後投資額	HKD 1,000		
Net Asset Value (NAV) Per Share 每股資產淨值	USD 4.1300 (Class A (USD) A(美元)類別)		
Benchmark <sup>**</sup> 基準指數 <sup>**</sup>	MSCI AC Zhong Hua NR USD index MSCI 明晟中華指數		


## Calendar Year Performance 年度表現

	2020	2019	2018	2017	2016
Class A (USD) A(美元)類別	42.66%	21.88%	-16.35%	55.93%	-1.88%
Benchmark 基準指數	25.13%	20.71%	-16.25%	49.35%	1.52%

## Cumulative Performance 累積表現

	YTD 年初至今	3 months 三個月	1 yr. 一年	3 yrs. 三年	5 yrs. 五年	Since Launch 成立至今
Class A (USD) A(美元)類別	3.30%	3.86%	32.87%	46.55%	144.81%	409.03%
Benchmark 基準指數	3.07%	2.38%	27.71%	32.92%	103.99%	401.98%

## 5-Year Cumulative Performance 五年累積表現



## Top Holdings 主要持有成份

Tencent Holdings Ltd.	6.76%
Alibaba Group Holding Ltd.	5.79%
AIA Group Limited	4.60%
Meituan	3.95%
Hong Kong Exchanges & Clearing Ltd.	3.00%
Bilibili Inc.	2.82%
I-MAB Sponsored ADR	2.80%
China Merchants Bank Co. Ltd.	2.73%
Wuxi Biologics (Cayman) Inc.	2.45%
Ping An Insurance (Group) Company of China Ltd.	2.13%

Geographical Breakdown<sup>~</sup>

China 中國	83.39%
Hong Kong 香港	13.34%
Cash & Cash Equivalents 現金及現金等值資產	3.27%

Sector Breakdown<sup>~</sup>

Consumer Discretionary 非日常生活消費品	27.54%
Communication Services 通訊服務	16.03%
Financials 金融	13.60%
Healthcare 醫療保健	11.17%
Materials 物料	7.97%
Real Estate 房地產	6.37%
Information Technology 資訊科技	6.34%
Industrials 工業	4.34%
Consumer Staples 日常消費品	3.36%
Cash & Cash Equivalents 現金及現金等值資產	3.27%

Source: Manulife Investment Management (Hong Kong) Limited unless otherwise indicated. All the performance figures are on NAV to NAV basis, in base currency with dividends reinvested. The sourced information contained herein is not warranted to be accurate, complete or timely. Neither Manulife Investment Management (Hong Kong) Limited nor any of its affiliates are responsible for any damages or losses arising from any use of this information. 資料來源：宏利投資管理(香港)有限公司或另有說明。所有的業績數據以資產淨值對資產淨值及基礎貨幣計算，股息再投資。本文件內所提供的資料並未就其準確性、完整性、及時性作出保證。宏利投資管理(香港)有限公司及其任何聯繫公司均不負責任何因使用該等資料而引致的損害及損失。

<sup>~</sup> This fund name was last changed in August 2009. 於2009年8月，本基金名稱作最近一次更改。

<sup>\*</sup> Management Fee may be increased to a maximum of 6% of the Net Asset Value of the relevant Fund by giving not less than three months' prior notice of the proposed increase to the Depositary and to the Shareholders of the relevant Fund. Please refer to the Fund prospectus for details. 管理費可增加到最高為有關基金的資產淨值的6%，但須就擬作出的增加給予存管處及有關基金的股東至少三個月的事先通知。詳情請參閱本基金的基金章程。

<sup>\*\*</sup> The benchmark was changed from FTSE Hong Kong Index to the current one in August 2009. 於2009年8月，基準指數由當時香港指數更改至現時之指數。

<sup>~</sup> Due to rounding, the total may not be equal to 100%. A negative percentage, if any, represents a short position in the portfolio for hedging/cash flow management purposes. Please refer to offering document of the Fund for details. 數字經修整後，總計可能並不相等於100%。負數百分比(如有)代表投資組合為了對沖或現金流管理而持有短倉。有關詳情請參閱本基金之銷售文件。

This fund invests in a single geographic region and companies listed on the Growth Enterprise Market, which may involve concentration, liquidity and volatility risks. Investors may potentially expose to capital loss. 本基金投資於單一地區及創業板上公司，可能涉及集中性、流動性及波動性風險。投資者或須承受資本虧損。